Biotron
- Short interest
- 0.03%
- +0.01 pp 30d
- as of 20 Nov 2025
- Reported shorts
- 421.6K
- Shares on issue
- 1.526B
Biotron (BIT) Short Interest
Biotron (ASX:BIT) had 0.03% of shares reported as short positions as of 20 Nov 2025, representing 421,583 shares. Biotron operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4About Biotron
Biotron Limited is an Australian biotechnology company focused on developing and commercializing antiviral therapies. Their lead compound, BIT225, is in Phase 2 development for HIV-1 and Hepatitis C, targeting viroporin proteins crucial for viral pathogenicity. The company leverages a proprietary screening platform and has a library of compounds with potential against various viral diseases, including SARS-CoV-2.
Company profile →Biotron (ASX:BIT) has 0.03% of its shares on issue reported as short positions as of 20 Nov 2025, or about 421,583 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. Its highest recorded short interest was 0.16% in February 2023. BIT is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Short interest
History & FAQ →Weekly context: The 10 most shorted ASX stocks — Week 41, 2026.
Strategy fit
How each stock picker strategy reads BIT today
- Zanger BreakoutWatchScore 6rank 1900 of 1942
- CAN SLIMNot a candidate
- Minervini Trend TemplateWatchScore 8rank 1474 of 1716
- Crowded-Short BreakoutWatchScore 9rank 1089 of 1500
- Quality compoundersNot a candidate
Prices to 14 Oct 2026 · Mechanical readings of published rules, not recommendations · Not financial adviceFull strategy readings →
BIT fundamentals
In the year to 30 Jun 2026, Biotron (ASX:BIT) recorded revenue of A$0 and a net loss after tax of A$1.5M. A year earlier it recorded revenue of A$0 and a net loss after tax of A$318.6K. Figures are in AUD, the company's reporting currency; source: ASX (Markit), as at 14 Oct 2026.
Full statements, ratios and filings are on the Financials tab. Not financial advice.
Latest BIT news
All news- Appointment of CEO and Executive Director
asx · 13 Oct 2026
- Resignation of Managing Director and Appendix 3Z
asx · 13 Sept 2026
- Change of Share Registry
asx · 3 Sept 2026
Company details
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss BIT
Start a research thread or post the first pulse update